Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 24
Encontrada(s) 1 página(s)

ABACUS. Repositorio de Producción Científica
Publicación Artículo científico (JournalArticle)

Persistent Symptoms (Lasting Longer than 1 Year) in Children Hospitalized with Acute COVID-19 Versus Other Conditions

  • Conde, Marta
  • Gastesi, Irati
  • Pablo, Lucía de
  • Villanueva Medina, Sara
  • Aguilera Alonso, David
  • Esteban Vázquez, Ana
  • Epalza, Cristina
  • López, María
  • Domínguez Rodríguez, Sara
  • Tagarro García, Alfredo
  • et al.
We evaluated the prevalence and characteristics of persistent signs and/or symptoms in children and young people (CYP) one year after hospitalization for acute COVID-19 compared with a control group of CYP hospitalized for other conditions. We identified a nonsignificant difference in the prevalence of persistent symptoms 1 year after hospitalization between children and young people (CYP) with acute COVID-19 and those hospitalized for non-COVID-19 related conditions.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort

  • Giannella, Maddalena
  • Righi, Elda
  • Pascale, Renato
  • Rinaldi, Matteo
  • Caroccia, Natascia
  • Gamberini, Chiara
  • Palacios-Baena, Zaira Raquel
  • Caponcello, Maria Giulia
  • Morelli, María Cristina
  • Tamè, Mariarosa
  • Busutti, Marco
  • Pascual Bravo, Alberto
Previous studies assessing the antibody response (AbR) to mRNA COVID-19 vaccines in solid organ transplant (SOT) recipients are limited by short follow-up, hampering the analysis of AbR kinetics. We present the ORCHESTRA SOT recipients cohort assessed for AbR at first dose (t0), second dose (t1), and within 3 ± 1 month (t2) after the first dose. We analyzed 1062 SOT patients (kidney, 63.7%; liver, 17.4%; heart, 16.7%; and lung, 2.5%) and 5045 health care workers (HCWs). The AbR rates in the SOTs and HCWs were 52.3% and 99.4%. The antibody levels were significantly higher in the HCWs than in the SOTs (p < 0.001). The kinetics showed an increase (p < 0.001) in antibody levels up to 76 days and a non-significant decrease after 118 days in the SOT recipients versus a decrease up to 76 days (p = 0.02) and a less pronounced decrease between 76 and 118 days (p = 0.04) in the HCWs. Upon multivariable analysis, liver transplant, ≥3 years from SOT, mRNA-1273, azathioprine, and longer time from t0 were associated with a positive AbR at t2. Older age, other comorbidities, mycophenolate, steroids, and impaired graft function were associated with lower AbR probability. Our results may be useful to optimize strategies of immune monitoring after COVID-19 vaccination and indications regarding timing for booster dosages calibrated on SOT patients’ characteristics., The ORCHESTRA project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 101016167, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Association of Patients' Epidemiological Characteristics and Comorbidities with Severity and Related Mortality Risk of SARS-CoV-2 Infection: Results of an Umbrella Systematic Review and Meta-Analysis

  • Reyna-Villasmil, Eduardo
  • Caponcello, Maria Giulia
  • Maldonado, Natalia
  • Olivares Navarro, Paula
  • Caroccia, Natascia
  • Bonazzetti, Cecilia
  • Tazza, Beatrice
  • Carrara, Elena
  • Giannella, Maddalena
  • Tacconelli, Evelina
  • Rodríguez-Baño, Jesús
  • Palacios-Baena, Zaira Raquel
The objective of this study was to assess the association between patients’ epidemiological characteristics and comorbidities with SARS-CoV-2 infection severity and related mortality risk. An umbrella systematic review, including a meta-analysis examining the association between patients’ underlying conditions and severity (defined as need for hospitalization) and mortality of COVID-19, was performed. Studies were included if they reported pooled risk estimates of at least three underlying determinants for hospitalization, critical disease (ICU admission, mechanical ventilation), and hospital mortality in patients diagnosed with SARS-CoV-2 infection. Evidence was summarized as pooled odds ratios (pOR) for disease outcomes with 95% confidence intervals (95% CI). Sixteen systematic reviews investigating the possible associations of comorbidities with severity or death from COVID-19 disease were included. Hospitalization was associated with age > 60 years (pOR 3.50; 95% CI 2.97−4.36), smoking habit (pOR 3.50; 95% CI 2.97−4.36), and chronic pulmonary disease (pOR 2.94; 95% CI 2.14−4.04). Chronic pulmonary disease (pOR 2.82; 95% CI 1.92−4.14), cerebrovascular disease (pOR 2.74; 95% CI 1.59−4.74), and cardiovascular disease (pOR 2.44; 95% CI 1.97−3.01) were likely to be associated with increased risk of critical COVID-19. The highest risk of mortality was associated with cardiovascular disease (pOR 3.59; 95% CI 2.83−4.56), cerebrovascular disease (pOR 3.11; 95% CI 2.35−4.11), and chronic renal disease (pOR 3.02; 95% CI 2.61−3.49). In conclusion, this umbrella systematic review provides a comprehensive summary of meta-analyses examining the impact of patients’ characteristics on COVID-19 outcomes. Elderly patients and those cardiovascular, cerebrovascular, and chronic renal disease should be prioritized for pre-exposure and post-exposure prophylaxis and early treatment., This systematic review was developed as part of the ORCHESTRA project (Connecting European Cohorts to increase common and effective SARS-CoV-2 Response), which was funded by the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement no. 101016167)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis

  • Carrara, Elena
  • Razzaboni, Elisa
  • Azzini, Anna Maria
  • De Rui, Maria Elena
  • Pinho Guedes, Mariana Nunes
  • Gorska, Anna
  • Giannella, Maddalena
  • Bussini, Linda
  • Bartoletti, Michele
  • Arbizzani, Federica
  • Palacios-Baena, Zaira Raquel
  • Caponcello, Maria Giulia
  • Maldonado, Natalia
  • Rodríguez-Baño, Jesús
  • Visco, Carlo
  • Krampera, Mauro
  • Tacconelli, Evelina
Main aim of this systematic review is to quantify the risk and identify predictors of clinical evolution of SARS-CoV-2 in hematological patients compared to different control populations. Two independent reviewers screened the literature assessing clinical outcomes of SARS-CoV-2 infection in adult patients with active hematological malignancies published up to June 2021. Primary outcome was COVID-19 related mortality, secondary outcomes were hospital and intensive-care admission, mechanical ventilation (MV), and thromboembolic events. Variables related to study setting, baseline patients' demographic, comorbidities, underlying hematological disease, ongoing chemotherapy, COVID-19 presentation, and treatments were extracted. A total of 67 studies including 10,061 hematological patients and 111,143 controls were included. Most of the studies were retrospective cohorts (51 studies, 76%) and only 19 (13%) provided data for a control group. A significant increased risk of clinical progression in the hematological population compared to the controls was found in terms of COVID-19 related mortality (OR, 2.12; 95% CI, 1.77-2.54), hospitalization (OR, 1.98; 95% CI, 1.15-3.43), intensive-care admission (OR, 1.77; 95% CI, 1.38-2.26), and MV (OR, 2.17; 95% CI, 1.71-2.75). The risk remained significantly higher in the subgroup analysis comparing hematological patients versus solid cancer. Meta-regression analysis of uncontrolled studies showed that older age, male sex, and hypertension were significantly related to worse clinical outcomes of COVID-19 in hematological population. Older age and hypertension were found to be associated also to thromboembolic events. In conclusion, hematological patients have a higher risk of COVID-19 clinical progression compared to both the general population and to patients with solid cancer., This work has been financed by the ORCHESTRA project under the European Union's Horizon 2020 research and innovation program Grant Agreement No. 101016167., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort

  • Gentilotti, Elisa
  • Górska, Anna
  • Tami, Adriana
  • Gusinow, Roy
  • Mirandola, Massimo
  • Rodríguez-Baño, Jesús
  • Palacios-Baena, Zaira Raquel
  • Rossi, Elisa
  • Hasenauer, Jan
  • Lopes-Rafegas, Iris
  • Righi, Elda
  • Caroccia, Natascia
  • Cataudella, Salvatore
  • Pasquini, Zeno
  • Osmo, Thomas
  • Piccolo, Lidia Del
  • Savoldi, Alessia
  • Kumar-Singh, Samir
  • Mazzaferri, Fulvia
  • Caponcello, Maria Giulia
  • Boer, Gerolf de
  • Hara, Gabriel Levy
  • ORCHESTRA Study Groupt
  • Nardo, Pasquale De
  • Malhotra, Surbhi
  • Canziani, Lorenzo Maria
  • Ghosn, Jade
  • Florence, Aline-Marie
  • Lafhej, Nadhem
  • van der Gun, Bernardina T. F.
  • Giannella, Maddalena
  • Laouénan, Cédric
  • Tacconelli, Evelina
© 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., [Background] Lack of specific definitions of clinical characteristics, disease severity, and risk and preventive factors of post-COVID-19 syndrome (PCS) severely impacts research and discovery of new preventive and therapeutics drugs., [Methods] This prospective multicenter cohort study was conducted from February 2020 to June 2022 in 5 countries, enrolling SARS-CoV-2 out- and in-patients followed at 3-, 6-, and 12-month from diagnosis, with assessment of clinical and biochemical features, antibody (Ab) response, Variant of Concern (VoC), and physical and mental quality of life (QoL). Outcome of interest was identification of risk and protective factors of PCS by clinical phenotype, setting, severity of disease, treatment, and vaccination status. We used SF-36 questionnaire to assess evolution in QoL index during follow-up and unsupervised machine learning algorithms (principal component analysis, PCA) to explore symptom clusters. Severity of PCS was defined by clinical phenotype and QoL. We also used generalized linear models to analyse the impact of PCS on QoL and associated risk and preventive factors. CT registration number: NCT05097677., [Findings] Among 1796 patients enrolled, 1030 (57%) suffered from at least one symptom at 12-month. PCA identified 4 clinical phenotypes: chronic fatigue-like syndrome (CFs: fatigue, headache and memory loss, 757 patients, 42%), respiratory syndrome (REs: cough and dyspnoea, 502, 23%); chronic pain syndrome (CPs: arthralgia and myalgia, 399, 22%); and neurosensorial syndrome (NSs: alteration in taste and smell, 197, 11%). Determinants of clinical phenotypes were different (all comparisons p < 0.05): being female increased risk of CPs, NSs, and CFs; chronic pulmonary diseases of REs; neurological symptoms at SARS-CoV-2 diagnosis of REs, NSs, and CFs; oxygen therapy of CFs and REs; and gastrointestinal symptoms at SARS-CoV-2 diagnosis of CFs. Early treatment of SARS-CoV-2 infection with monoclonal Ab (all clinical phenotypes), corticosteroids therapy for mild/severe cases (NSs), and SARS-CoV-2 vaccination (CPs) were less likely to be associated to PCS (all comparisons p < 0.05). Highest reduction in QoL was detected in REs and CPs (43.57 and 43.86 vs 57.32 in PCS-negative controls, p < 0.001). Female sex (p < 0.001), gastrointestinal symptoms (p = 0.034) and renal complications (p = 0.002) during the acute infection were likely to increase risk of severe PCS (QoL <50). Vaccination and early treatment with monoclonal Ab reduced the risk of severe PCS (p = 0.01 and p = 0.03, respectively)., [Interpretation] Our study provides new evidence suggesting that PCS can be classified by clinical phenotypes with different impact on QoL, underlying possible different pathogenic mechanisms. We identified factors associated to each clinical phenotype and to severe PCS. These results might help in designing pathogenesis studies and in selecting high-risk patients for inclusion in therapeutic and management clinical trials., The study received funding from the Horizon 2020 ORCHESTRA project, grant 101016167; from the Netherlands Organisation for Health Research and Development (ZonMw), grant 10430012010023; from Inserm, REACTing (REsearch & ACtion emergING infectious diseases) consortium and the French Ministry of Health, grant PHRC 20-0424., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

How European Research Projects Can Support Vaccination Strategies: The Case of the ORCHESTRA Project for SARS-CoV-2

  • Azzini, Anna Maria
  • Canziani, Lorenzo Maria
  • Davis, Ruth Joanna
  • Mirandola, Massimo
  • Hoelscher, Michael
  • Meyer, Laurence
  • Laouénan, Cédric
  • Giannella, Maddalena
  • Rodríguez-Baño, Jesús
  • Boffetta, Paolo
  • Mates, Dana
  • Malhotra-Kumar, Surbhi
  • Scipione, Gabriella
  • Stellmach, Caroline
  • Rinaldi, Eugenia
  • Hasenauer, Jan
  • Tacconelli, Evelina
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., ORCHESTRA (“Connecting European Cohorts to Increase Common and Effective Response To SARS-CoV-2 Pandemic”) is an EU-funded project which aims to help rapidly advance the knowledge related to the prevention of the SARS-CoV-2 infection and the management of COVID-19 and its long-term sequelae. Here, we describe the early results of this project, focusing on the strengths of multiple, international, historical and prospective cohort studies and highlighting those results which are of potential relevance for vaccination strategies, such as the necessity of a vaccine booster dose after a primary vaccination course in hematologic cancer patients and in solid organ transplant recipients to elicit a higher antibody titer, and the protective effect of vaccination on severe COVID-19 clinical manifestation and on the emergence of post-COVID-19 conditions. Valuable data regarding epidemiological variations, risk factors of SARS-CoV-2 infection and its sequelae, and vaccination efficacy in different subpopulations can support further defining public health vaccination policies., The ORCHESTRA project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 101016167., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Scalable Pseudonymization Tool for Rapid Deployment in Large Biomedical Research Networks: Development and Evaluation Study

  • Abu Attieh, Hammam
  • Neves, Diogo Telmo
  • Guedes, Mariana
  • Mirandola, Massimo
  • Dellacasa, Chiara
  • Rossi, Elisa
  • Prasser, Fabian
The SARS-CoV-2 pandemic has demonstrated once again that rapid collaborative research is essential for the future of biomedicine. Large research networks are needed to collect, share, and reuse data and biosamples to generate collaborative evidence. However, setting up such networks is often complex and time-consuming, as common tools and policies are needed to ensure interoperability and the required flows of data and samples, especially for handling personal data and the associated data protection issues. In biomedical research, pseudonymization detaches directly identifying details from biomedical data and biosamples and connects them using secure identifiers, the so-called pseudonyms. This protects privacy by design but allows the necessary linkage and reidentification., This work has been funded by the European Union’s Horizon 2020 research and innovation programme under the project ORCHESTRA (grant agreement 101016167)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study

  • Infante-Domínguez, Carmen
  • Salto-Alejandre, Sonsoles
  • Álvarez-Marín, Rocío
  • Sabé, Nuria
  • Ramos-Martínez, Antonio
  • Moreno, Asunción
  • Ferreira de Moraes, Kamilla
  • Palacios-Baena, Zaira Raquel
  • Muñoz, Patricia
  • Fernández-Ruiz, Mario
  • Blanes, Marino
  • Fariñas, María del Carmen
  • Vidal, Elisa
  • Merino de Lucas, Esperanza
  • Halpern, Márcia
  • Hernández-Gallego, Román
  • Bassetti, Matteo
  • Mularoni, Alessandra
  • Gutiérrez-Dalmau, Alex
  • Rinaldi, Matteo
  • Jiménez-Jorge, Silvia
  • Bodro, Marta
  • Aranha-Camargo, Luis Fernando
  • Valerio, Maricela
  • Sánchez-Céspedes, Javier
  • Gutiérrez-Gutiérrez, Belén
  • Giannella, Maddalena
  • Rodríguez-Baño, Jesús
  • Pachón, Jerónimo
  • Cordero, Elisa
Clinical phenotypes of COVID-19, associated with mortality risk, have been identified in the general population. The present study assesses their applicability in solid organ transplant recipients (SOTR) hospital-admitted by COVID-19. In a cohort of 488 SOTR, nonvaccinated (n = 394) and vaccinated (n = 94) against SARS-CoV-2, we evaluated 16 demographic, clinical, analytical, and radiological variables to identify the clinical phenotypes A, B, and C. The median age was 61.0 (51-69) years, 330 (67.6%) and 158 (32.4%) were men and women, respectively, 415 (85%) had pneumonia, and 161 (33%) had SpO2 < 95% at admission. All-cause mortality occurred in 105 (21.5%) cases. It was higher in nonvaccinated versus vaccinated SOTR (23.4% vs 13.8%, P = 0.04). Patients in the entire cohort were classified into phenotypes A (n = 149, 30.5%), B (n = 187, 38.3%), and C (n = 152, 31.1%), with mortality rates of 8.7%, 16.6%, and 40.1%, respectively, which were similar to those of nonvaccinated SOTR (9.5%, 16.7%, and 52.0%) and lower in vaccinated SOTR (4.4%, 15.8%, and 17.3%, respectively), with difference between nonvaccinated and vaccinated in the phenotype C (P < 0.001). In conclusion, COVID-19 clinical phenotypes are useful in SOTR, and all-cause mortality decreases in vaccinated patients., This study was supported by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI, RD16/0016/0001 [JR-B, BG-G], RD16/0016/0005 [NS], and RD16/0016/0009 [JP, EC, JSC]), co-financed by European Development Regional Fund “A way to achieve Europe”, Operative Program Intelligence Growth 2014-2020. EC, JSC and JR-B received grants from the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Proyectos de Investigación sobre el SARS-CoV-2 y la enfermedad COVID-19 (COV20/00370, COV20/00580, COV20/01031). EC and JSC also were supported by the grant IM22/INF/13 from the CIBERINFEC, Instituto de Salud Carlos III, Spain. This study was also supported by CIBERINFEC - Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU (EC and JS-C [CB21/13/00006], BG-G and JR-B (CB21/13/00012). JSC is a researcher belonging to the program “Nicolás Monardes” (RC-0002–2022), Servicio Andaluz de Salud, Junta de Andalucía, Spain. The ORCHESTRA project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016167., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ORCHESTRA Delphi Consensus: Diagnostic and Therapeutic Management of SARS-CoV-2 Infection in Solid Organ Transplant Recipients

  • Tazza, Beatrice
  • Caroccia, Natascia
  • Toschi, Alice
  • Pascale, Renato
  • Gkrania-Klotsas, Effrosyni
  • Olivares Navarro, Paula
  • Canziani, Lorenzo Maria
  • Tavelli, Alessandro
  • Antinori, Andrea
  • Grossi, Paolo Antonio
  • Peghin, Maddalena
  • Tacconelli, Evelina
  • Palacios-Baena, Zaira Raquel
  • Viale, Pierluigi
  • Giannella, Maddalena
In Press, Journal Pre-proof, Our aim was to address existing knowledge gaps regarding risk stratification, best use of diagnostic resources, optimal treatment and general management of SARS-CoV-2 infection in solid organ transplant (SOT) recipients. As high-quality evidence specific to this fragile population is lacking, our final aim was to provide an expert consensus evidence-informed guidance that can aid clinicians in their daily practice., This work was supported by the European Union’s Horizon 2020 Research and Innovation Program, grant agreement 101016167, within the ORCHESTRA project (EU H2020 ORCHESTRA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Quasi-species prevalence and clinical impact of evolving SARS-CoV-2 lineages in European COVID-19 cohorts, January 2020 to February 2022

  • Berkell, Matilda
  • Górska, Anna
  • Smet, Mathias
  • Bachelet, Delphine
  • Gentilotti, Elisa
  • Guedes, Mariana
  • Franco-Yusti, Anna Maria
  • Mazzaferri, Fulvia
  • Forero, Erley Lizarazo
  • Matheeussen, Veerle
  • Visseaux, Benoit
  • Palacios-Baena, Zaira Raquel
  • Caroccia, Natascia
  • Florence, Aline-Marie
  • Charpentier, Charlotte
  • van Leer, Coretta
  • Giannella, Maddalena
  • Friedrich, Alex W.
  • Rodríguez-Baño, Jesús
  • Ghosn, Jade
  • Kumar-Singh, Samir
  • Laouénan, Cedric
  • Tacconelli, Evelina
  • Malhotra-Kumar, Surbhi
BackgroundEvolution of SARS-CoV-2 is continuous.AimBetween 01/2020 and 02/2022, we studied SARS-CoV-2 variant epidemiology, evolution and association with COVID-19 severity.MethodsIn nasopharyngeal swabs of COVID-19 patients (n = 1,762) from France, Italy, Spain, and the Netherlands, SARS-CoV-2 was investigated by reverse transcription-quantitative PCR and whole-genome sequencing, and the virus variant/lineage (NextStrain/Pangolin) was determined. Patients' demographic and clinical details were recorded. Associations between mild/moderate or severe COVID-19 and SARS-CoV-2 variants and patient characteristics were assessed by logistic regression. Rates and genomic locations of mutations, as well as quasi-species distribution (≥ 2 heterogeneous positions, ≥ 50× coverage) were estimated based on 1,332 high-quality sequences.ResultsOverall, 11 SARS-CoV-2 clades infected 1,762 study patients of median age 59 years (interquartile range (IQR): 45-73), with 52.5% (n = 925) being male. In total, 101 non-synonymous substitutions/insertions correlated with disease prognosis (severe, n = 27; mild-to-moderate, n = 74). Several hotspots (mutation rates ≥ 85%) occurred in Alpha, Delta, and Omicron variants of concern (VOCs) but none in pre-Alpha strains. Four hotspots were retained across all study variants, including spike:D614G. Average number of mutations per open-reading-frame (ORF) increased in the spike gene (average < 5 per genome in January 2020 to > 15 in 2022), but remained stable in ORF1ab, membrane, and nucleocapsid genes. Quasi-species were most prevalent in 20A/EU2 (48.9%), 20E/EU1 (48.6%), 20A (38.8%), and 21K/Omicron (36.1%) infections. Immunocompromised status and age (≥ 60 years), while associated with severe COVID-19 or death irrespective of variant (odds ratio (OR): 1.60-2.25; p ≤ 0.014), did not affect quasi-species' prevalence (p > 0.05).ConclusionSpecific mutations correlate with COVID-19 severity. Quasi-species potentially shaping VOCs' emergence are relevant to consider., This study was funded by the ORCHESTRA project (https:// orchestra-cohort.eu/) through the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016167, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ORCHESTRA Delphi consensus: diagnostic and therapeutic management of post-COVID-19 condition in vulnerable populations

  • Gentilotti, Elisa
  • Canziani, Lorenzo Maria
  • Caponcello, Maria Giulia
  • Azzini, Anna Maria
  • Savoldi, Alessia
  • De Nardo, Pasquale
  • Palacios-Baena, Zaira Raquel
  • Tazza, Beatrice
  • Caroccia, Natascia
  • Marchetti, Giulia Carla
  • Antinori, Andrea
  • Giannella, Maddalena
  • Rodríguez-Baño, Jesús
  • Tacconelli, Evelina
Post-COVID-19 condition (PCC) remains poorly understood, especially in clinically vulnerable groups. We applied the Delphi approach to drive recommendations for the diagnosis, management, and prevention of PCC in people living with HIV (PWH) and patients affected by rheumatological diseases (RD) and haematological malignancies., This work was supported by the European Union’s Horizon 2020 Research and Innovation Program, grant agreement 101016167, within the ORCHESTRA project (EU H2020 ORCHESTRA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in patients with rheumatological diseases

  • Caponcello, Maria Giulia
  • Navarro, Paula Olivares
  • Bonazzetti, Cecilia
  • Campoli, Caterina
  • Savoldi, Alessia
  • Gentilotti, Elisa
  • Monforte, Antonella d'Arminio
  • Lo Caputo, Sergio
  • Otero-Varela, Lucía
  • Castrejón, Isabel
  • Tacconelli, Evelina
  • Rodríguez-Baño, Jesús
  • Palacios-Baena, Zaira Raquel
  • Mendoza Mendoza, Dolores
  • Moreira Navarrete, Virginia
  • Tomelleri, Alessandro
  • Ljung, Lotta
  • Rocha, Teresa Martins
  • Palma, Pedro
  • Salamanca-Rivera, Elena
  • Paniagua-García, María
  • Fassio, Angelo
  • Bixio, Riccardo
  • Tombetti, Enrico
  • Conti, Fabrizio
Objectives The clinical management of COVID-19 in immunocompromised patients remains a challenge. This work aimed to develop a consensus to establish recommendations for the clinical, diagnostic, and therapeutic management of patients with rheumatic diseases and COVID-19. Methods A panel of 14 international experts was selected, and Delphi methodology was used for the consensus, after a systematic literature review. Twenty-four questions were formulated and presented to the panel. The experts voted using a 6-point Likert scale (1) ‘Strongly disagree’ (SD); (2) ‘Disagree’ (D); (3) ‘Somewhat disagree’ (SWD); (4) ‘Somewhat agree’ (SWA); (5) ‘Agree’ (A); (6) ‘Strongly agree’ (SA). To establish consensus, simple or cumulative agreement ≥80% was required over a maximum of three rounds. Cumulative agreement was defined as the sum of response percentages on items 1–2 (SD + D); 2–3 (D + SWD); 4–5 (SWA + A); or 5–6 (A + SA), distinguishing a strong degree of agreement (A + SA) or disagreement (SD + D) from a moderate degree of agreement (SWA + A) or disagreement (D + SWD). Results After the three rounds, consensus was reached on 23 of the 24 questions and 10 recommendations were made. Discussion The Delphi methodology allowed consensus on recommendations in areas with insufficient scientific evidence, which can be considered for decision-making in the management of patients with rheumatological diseases while awaiting better evidence., This work was supported by the European Union's Horizon 2020 Research and Innovation Program, grant agreement 101016167, within the ORCHESTRA project (EU H2020 ORCHESTRA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in haematological patients

  • Canziani, Lorenzo Maria
  • Azzini, Anna Maria
  • Salmanton-García, Jon
  • Savoldi, Alessia
  • Caponcello, Maria Giulia
  • Pasquini, Zeno
  • Pagano, Livio
  • Cornely, Oliver A
  • Cingolani, Antonella
  • Mazzotta, Valentina
  • Cosentino, Federica
  • Rodríguez-Baño, Jesús
  • Krampera, Mauro
  • Tacconelli, Evelina
Objectives COVID-19 poses a significant risk to individuals with haematological malignancies (HM), as they are particularly vulnerable to severe disease progression and hospitalization due to their compromised immune systems. Many clinical decisions regarding the management of COVID-19 in these patients are yet to be fully addressed by existing guidelines, leading to variability in care. Methods A 28-item Delphi survey was developed to gather expert opinions on key areas of COVID-19 management in patients with HM, including risk stratification for severe COVID-19, diagnostic processes, and treatment decisions. Results Twenty-one experts with backgrounds in haematology and infectious diseases were enrolled. Of the 28 questions posed to the experts, consensus was reached on 15 statements. Discussion These Delphi consensus statements offer valuable suggestions with direct implications for clinical practice, addressing critical areas such as risk identification, appropriate diagnostic approaches, and tailored treatment strategies for patients with HM with COVID-19. The findings provide actionable insights that may help fill gaps in current scientific literature, enhancing patient care and decision-making in this high-risk population., This article was published as part of a supplement supported by the ORCHESTRA project. The ORCHESTRA project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101016167. The views expressed in this article are the sole responsibility of the author and the European Commission is not responsible for any use that may be made of the information it contains., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ORCHESTRA Delphi consensus: clinical management of SARS-CoV-2 infection in people with HIV

  • Tavelli, Alessandro
  • Vergori, Alessandra
  • Cingolani, Antonella
  • Bai, Francesca
  • Azzini, Anna Maria
  • Hara, Gabriel Levy
  • Caponcello, Maria Giulia
  • Rinaldi, Matteo
  • Palacios-Baena, Zaira Raquel
  • Gatti, Milo
  • Maccarrone, Gaia
  • Tacconelli, Evelina
  • Antinori, Andrea
  • Monforte, Antonella d'Arminio
Objectives The interaction between HIV and COVID-19 resulted in a syndemic that showed an excess burden of disease for people with HIV (PWH). Four years of the COVID-19 pandemic have raised many unsolved questions about the optimal care of COVID-19 in PWH. Methods We performed a study using a three-round Delphi methodology involving a panel of physicians with expertise in HIV and COVID-19 infections. The main aim of the study was to provide recommendations on critical clinical issues of COVID-19 among PWH and to inform physicians and policy-makers for improving care and prevention of COVID-19 in PWH. A total of 27 questions were conceived, focusing on four main areas of interest in the management of COVID-19 in PWH; a panel of 34 experts in HIV and COVID-19 care expressed their level of agreement on each item. Questions that received agreement/disagreement ≥79.4% of panellists were identified and statements were generated accordingly. Results Consensus was reached on 19/27 items, resulting in 18 final statements. These statements addressed: (a) risk of COVID-19 progression to severe disease among PWH; (b) COVID-19 diagnostics and laboratory procedures; (c) early treatments with antivirals and/or monoclonal antibodies; (d) use of corticosteroids; (e) COVID-19 preventive strategies. Discussion This consensus's study guides infectious diseases physicians in making decisions regarding the care of PWH for COVID-19, where results from the scientific literature are limited or conflicting., This work was supported by European Union's Horizon 2020 research and innovation programme under grant agreement no. 101016167, within the ORCHESTRA project. The views expressed in this article are the sole responsibility of the author and the commission is not responsible for any use that may be made of the information it contains., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bridging the evidence gap: expert consensus on management of SARS-CoV-2 acute infection and post-COVID-19 condition in immunocompromised patients

  • Canziani, Lorenzo M.
  • Monforte, Antonella d'Arminio
  • Giannella, Maddalena
  • Rodríguez-Baño, Jesús
  • Tacconelli, Evelina
The COVID-19 pandemic highlighted the inherent temporal disparity between the generation of reliable scientific evidence and the urgent clinical needs of patients, particularly those exhibiting significant, albeit less prevalent, comorbidities. This temporal lag frequently resulted in therapeutic decision-making under conditions of evidentiary scarcity. Immunocompromised individuals exhibit an elevated susceptibility to SARS-CoV-2 infection. However, the intersection of specific immunosuppressive comorbidities and COVID-19 is rarely characterized within COVID-19 research. This underrepresentation stems not only from the relatively low prevalence of these combined conditions but also from the inherent methodological complexities associated with conducting robust clinical investigations, particularly randomized controlled trials, within patient populations often characterized by high mortality rates and clinical heterogeneity., This article was published as part of a supplement supported by the ORCHESTRA project. The ORCHESTRA project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 101016167. The views expressed in this article are the sole responsibility of the author and the European Commission is not responsible for any use that may be made of the information it contains., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Risk Factors for Persisting SARS-CoV-2 Infection in Patients with B-Cell Malignancies in the Omicron Era: A Multicenter Cohort Study

  • Pasquini, Zeno
  • Toschi, Alice
  • Gibertoni, Dino
  • Amicucci, Armando
  • Casadei, Beatrice
  • Pellegrini, Cinzia
  • D'Abramo, Alessandra
  • De Marco, Patrizia
  • Bussini, Linda
  • Ciccone, Maria
  • Visentin, Alessandro
  • Olivares Navarro, Paula
  • Bartoletti, Michele
  • Nicastri, Emanuele
  • Krampera, Mauro
  • Zinzani, Pier Luigi
  • Bonifazi, Francesca
  • Viale, Pierluigi
  • Palacios-Baena, Zaira Raquel
  • Tacconelli, Evelina
  • Giannella, Maddalena
In Press, Journal Pre-proof, Background Patients with B-cell malignancies are at high risk of persisting SARS-CoV-2 infection, which may delay oncologic treatments and increase morbidity. We aimed to assess risk factors for persisting infection in this population. Methods We conducted a multicenter retrospective study across five tertiary hospitals between January 1, 2022, and January 1, 2023. Adult patients with B-cell malignancies and SARS-CoV-2 infection were included. Persisting infection was defined as viral shedding ≥21 days with clinical and/or radiological signs. Risk factors were evaluated through multivariable logistic regression. Results Among 307 patients, 26.1% developed persisting infection. The cohort included non-Hodgkin lymphoma (67.4%), chronic lymphocytic leukemia (19.2%), and Hodgkin lymphoma (9.1%). Independent risk factors included anti-CD20 therapy (OR 3.22; 95% CI 2.37-4.39; p<0.001), and hospital admission at diagnosis (OR 5.16; 95% CI 2.37-12.45; p<0.001). Early therapy with nirmatrelvir/ritonavir (OR 0.32; 95% CI 0.19–0.54; p<0.001), remdesivir (OR 0.26; 95% CI 0.18–0.37; p<0.001) and sotrovimab (OR 0.32; 95% CI 0.15–0.67; p=0.003) were protective. Mortality at 120 days was higher in the persisting group, though not statistically significant (12.5% vs. 8.4%; p=0.277). Conclusions Our findings help define risk factors for persisting SARS-CoV-2 infection and support early treatment in patients with B-cell malignancies., This work was supported by the European Union’s Horizon 2020 Research and Innovation Program, grant agreement 101016167, within the ORCHESTRA project (EU H2020 ORCHESTRA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis

  • Gatti, Milo
  • Rinaldi, Matteo
  • Bussini, Linda
  • Bonazzetti, Cecilia
  • Pascale, Renato
  • Pasquini, Zeno
  • Faní, Francesca
  • Pinho Guedes, Mariana Nunes
  • Azzini, Anna Maria
  • Carrara, Elena
  • Palacios-Baena, Zaira Raquel
  • Caponcello, Maria Giulia
  • Reyna-Villasmil, Eduardo
  • Tacconelli, Evelina
  • Rodríguez-Baño, Jesús
  • Viale, Pierluigi
  • Giannella, Maddalena
  • ORCHESTRA Study Groupt
The ORCHESTRA study group: Natascia Caroccia, Federica Arbizzani, Maria Eugenia Giacomini, Oana Vatamanu, Elisa Razzaboni, Maria Elena De Rui, Anna Gorska, Natalia Maldonado , Paula Olivares, David Gutiérrez-Campos, Ana Belén Martín-Gutiérrez, Virginia Palomo, Almudena Serna, [Background] A significant increased risk of complications and mortality in immunocompromised patients affected by COVID-19 has been described. However, the impact of COVID-19 in solid organ transplant (SOT) recipients is an issue still under debate, due to conflicting evidence that has emerged from different observational studies., [Objectives] We performed a systematic review with a meta-analysis to assess the clinical outcome in SOT recipients with COVID-19 compared with the general population., [Data sources] PubMed-MEDLINE and Scopus were independently searched until 13 October 2021., [Study eligibility criteria] Prospective or retrospective observational studies comparing clinical outcome in SOT recipients versus general populations affected by COVID-19 were included. The primary endpoint was 30-day mortality., [Participants] Participants were patients with confirmed COVID-19., [Methods] The quality of the included studies was independently assessed with the Risk of Bias in Non-randomized Studies of Interventions tool for observational studies. The meta-analysis was performed by pooling ORs retrieved from studies providing adjustment for confounders using a random-effects model with the inverse variance method. Multiple subgroups and sensitivity analyses were conducted to investigate the source of heterogeneity., [Results] A total of 3501 articles were screened, and 31 observational studies (N = 590 375; 5759 SOT recipients vs. 584 616 general population) were included in the meta-analyses. No difference in 30-day mortality rate was found in the primary analysis, including studies providing adjustment for confounders (N = 17; 3752 SOT recipients vs. 159 745 general population; OR: 1.13; 95% CI, 0.94–1.35; I2 = 33.9%). No evidence of publication bias was reported. A higher risk of intensive care unit admission (OR: 1.56; 95% CI, 1.03–2.63) and occurrence of acute kidney injury (OR: 2.50; 95% CI, 1.81–3.45) was found in SOT recipients., [Conclusions] No increased risk in mortality was found in SOT recipients affected by COVID-19 compared with the general population when adjusted for demographic and clinical features and COVID-19 severity., No conflicts of interest to declare. This systematic review was developed as part of the ORCHESTRA project cohort (Connecting European Cohorts to increase common and effective SARS-CoV-2 Response), receiving funding from the European Union's Horizon 2020 research and innovation program (Grant no. 101016167)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Persistent Low-Grade Inflammation and Post-COVID Condition: Evidence from the ORCHESTRA Cohort

  • Gentilotti, Elisa
  • Alvarez Garavito, Carolina
  • Górska, Anna
  • Gusinow, Roy
  • Canziani, Lorenzo Maria
  • De Nardo, Pasquale
  • Visentin, Alessandro
  • Caponcello, Maria Giulia
  • Di Chiara, Michela
  • Florence, Aline-Marie
  • de Boer, Gerolf
  • Cataudella, Salvatore
  • The Orchestra Study Group
  • Levy Hara, Gabriel
  • Tami, Adriana
  • Giannella, Maddalena
  • Laouénan, Cédric
  • Hasenauer, Jan
  • Rodríguez-Baño, Jesús
  • Tacconelli, Evelina
Background: Persistent low-grade inflammation has been proposed as part of the biological mechanisms underlying post-COVID condition (PCC), which can result in laboratory tests abnormalities. However, the accuracy of routine laboratory tests for the diagnosis and follow-up of PCC is still under discussion. Methods: Patients with SARS-CoV-2 infection enrolled in the prospective, multinational ORCHESTRA cohort study, which included both European and non-European countries, were followed up for 18 months after acute infection. Blood test results were collected at acute infection and at 6, 12, and 18 months. A multivariable analysis was performed to estimate the relationship between the alterations of biochemical markers and the presence of four distinct PCC phenotypes, identified previously through a principal component analysis-respiratory (RESc), chronic pain (CPc), chronic fatigue (CFc), and neurosensorial (NSc)-during follow-up. Furthermore, this study investigated the correlation between biochemical parameters measured during the acute phase and the subsequent development of PCC. Finally, the relationship between the severity of the acute infection and biochemical abnormalities observed during follow-up was assessed. Results: The cohort included 4587 patients, 58% male, with a mean age of 58.7 (±15.5) years. A robust multivariable analysis demonstrated that, compared to controls, patients with PCC, and in particular those in the RESc cluster, presented higher mean C-reactive protein (CRP) levels at the 12- and 18-month follow-up (p-value = 0.01). In each follow-up, CRP values in patients with PCC and RESc were above 3 mg/L, corresponding to those observed in low-grade inflammation (3-10 mg/L). The severity of COVID-19 acute infection was associated with increased levels of CRP, ferritin and LDH during follow-up (p < 0.001). Biochemistry abnormalities detected during the early stages of acute COVID-19 did not correlate with an increased risk of developing PCC and its phenotypes. Conclusions: In patients with the RESc PCC phenotype, identified through a principal component analysis, blood test abnormalities consistent with prolonged and sustained low-grade inflammation can be detected up to 18 months after acute infection, supporting its role in the pathogenesis of PCC. Based on these results, trials on anti-inflammatory drugs, together with symptom-tailored interventions for patients with RESc, should be planned to prove their effectiveness in managing PCC and improving patient outcomes., This study received funding from the Horizon 2020 ORCHESTRA project, Grant 101016167., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pan-European Fragile Populations Cohort for COVID-19: What Worked, What Didn't, and Lessons Learned

  • Tazza, Beatrice
  • Bonazzetti, Cecilia
  • Caroccia, Natascia
  • Di Chiara, Michela
  • Canziani, Lorenzo Maria
  • Azzini, Anna Maria
  • Palacios-Baena, Zaira Raquel
  • Olivares Navarro, Paula
  • Rodríguez-Baño, Jesús
  • Tacconelli, Evelina
  • Viale, Pierluigi
  • Giannella, Maddalena
The COVID-19 pandemic exposed the vulnerability of immunocompromised hosts and the scarcity of evidence guiding their management. Within the European Horizon 2020 ORCHESTRA project, a multinational consortium connected existing and new cohorts to harmonize data, laboratory methods, and clinical expertise across fragile populations. The fragile patients' cohort became a model for how collaborative infrastructure can generate actionable evidence during a crisis. Through prospective follow-up and centralized immunologic assessment, ORCHESTRA defined the clinical spectrum of COVID-19 in transplant recipients, identified vaccine-modified disease phenotypes, and clarified the kinetics and correlates of immune protection. The project also demonstrated the feasibility of real-time immunologic monitoring, the value of data interoperability, and the need for adaptive harmonization across health systems. Integrating these results through Delphi consensus, ORCHESTRA translated research into practice, providing pragmatic guidance for clinicians across Europe. This experience underscores that harmonized, multidisciplinary research-rooted in collaboration and flexibility-can transform variability into knowledge and ultimately improve care for the most immunologically fragile patients., This work was supported by the European Union's Horizon 2020 Research and Innovation Program, grant agreement 101016167, within the ORCHESTRA project (EU H2020 ORCHESTRA)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project

  • Spiteri, Gianluca
  • D'Agostini, Marika
  • Abedini, Mahsa
  • Ditano, Giorgia
  • Collatuzzo, Giulia
  • Boffetta, Paolo
  • Vimercati, Luigi
  • Sansone, Emanuele
  • De Palma, Giuseppe
  • Modenese, Alberto
  • Gobba, Fabriziomaria
  • Liviero, Filippo
  • Moretto, Angelo
  • dell'Omo, Marco
  • Fiordi, Tiziana
  • Larese Filon, Francesca
  • Mauro, Marcella
  • Violán, Concepció|||0000-0003-3309-5360
  • Mates, Dana
  • Oravec Bérešová, Jana
  • Carta, Angela
  • Verlato, Giuseppe|||0000-0001-5262-8818
  • Porru, Stefano
Purpose: Anti SARS-CoV-2 vaccination initially showed high effectiveness in preventing COVID-19. However, after the surge of variants of concern, the effectiveness dropped. Several studies investigated if this was related to the decrease of the humoral response over time; however, this issue is still unclear. The aim of this study was to understand whether SARS-CoV-2 anti-S IgG levels can be used to predict breakthrough infection risk and define the timing for further booster doses administration. Method: Within the framework of the ORCHESTRA Project, over 20,000 health workers from 11 European centers were enrolled since December 2020. We performed two Cox proportional hazards survival analyses regarding pre-Omicron (from January to July 2021) and Omicron (December 2021-May 2022) periods. The serological response was classified as high (above the 75th percentile), medium (25th-75th), or low (< 25th). Results: Seventy-four (0.33%) and 2122 (20%) health workers were infected during the first and second periods, respectively. Both Cox analyses showed that having high anti-S titer was linked to a significantly lower risk of infection as compared to having medium serological response [HR of high vs medium anti-S titer = 0.27 (95% CI 0.11-0.66) during the first phase, HR = 0.76 (95% CI 0.62-0.93) during the second phase]. Conclusion: Vaccine effectiveness wanes significantly after new variants surge, making anti-S titer unsuitable to predict optimal timing for further booster dose administration. Studies on other immunological indicators, such as cellular immunity, are therefore needed to better understand the mechanisms and duration of protection against breakthrough infection risk.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Incidence and determinants of symptomatic and asymptomatic SARS-CoV-2 breakthrough infections after booster dose in a large European multicentric cohort of health workers-ORCHESTRA project

  • Porru, S.
  • Monaco, M. G. L.
  • Spiteri, G.
  • Tardón García, Adonina|||0000-0001-5150-1209
  • Rodríguez Suárez, Marta María
  • Orchestra WP5 Working Group
The ORCHESTRA project is funded by the European Commission, Horizon 2020 Program, Grant Agreement No. 101016167. The Verona and Oviedo cohorts were also supported by the Regional Health Authority (Azienda Zero), Veneto Region, Italy, and by the Health Research Institute of Asturias (ISPA), Spain, respectively. The Northern Barcelona cohort has been funded by the regional Ministry of Health of the Generalitat de Catalunya (Spain) (Called COVID19- PoC SLT16_04)., Porru S, Monaco MGL, Spiteri G, Carta A, Caliskan G, Violán C, Torán-Monserrat P, Vimercati L, Tafuri S, Boffetta P, Violante FS, Sala E, Sansone E, Gobba F, Casolari L, Wieser A, Janke C, Tardon A, Rodriguez-Suarez MM, Liviero F, Scapellato ML, dell'Omo M, Murgia N, Mates D, Calota VC, Strhársky J, Mrázová M, Pira E, Godono A, Magnano GC, Negro C, Verlato G; Orchestra WP5 Working Group
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Determinants of Anti-S Immune Response at 9 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project

  • Collatuzzo, G.
  • Lodi, V.
  • Feola, D.
  • Fernández Tardón, Guillermo|||0000-0002-7680-158X
This project has received funding from the EU Horizon 2020 research and innovation program under the ORCHESTRA project Grant Agreement No. 101016167. The cohort from Verona is funded by the Regional Health Authority (Azienda Zero), Veneto Region, Italy., Collatuzzo G., Lodi V., Feola D., De Palma G., Sansone E., Sala E., Janke C., Castelletti N., Porru S., Spiteri G., Monaco M.G.L., Larese Filon F., Negro C., Cegolon L., Beresova J., Fabianova E., Carrasco-Ribelles L.A., Toràn-Monserrat P., Rodriguez-Suarez M.M., Fernandez-Tardon G., Asafo S.S., Ditano G., Abedini M., Boffetta P.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 breakthrough infections: incidence and risk factors in a large European multicentric cohort of health workers

  • Porru, S.
  • Monaco, M. G. L.
  • Spiteri, G.
  • Tardón García, Adonina|||0000-0001-5150-1209
  • Rodríguez Suárez, Marta María
  • Fernández Tardón, Guillermo|||0000-0002-7680-158X
  • Jimeno Demuth, Francisco José
  • Castro Delgado, Rafael|||0000-0001-9520-656X
  • Iglesias Cabo, Tania|||0000-0002-0208-4880
European Commission, H2020 [101016167]; Regional Health Authority (Azienda Zero), Veneto Region, Italy; Health Research Institute of Asturias (ISPA), Spain, Porru S, Monaco MGL, Spiteri G, Carta A, Pezzani MD, Lippi G, Gibellini D, Tacconelli E, Dalla Vecchia I, Sala E, Sansone E, De Palma G, Bonfanti C, Lombardo M, Terlenghi L, Pira E, Mansour I, Coggiola M, Ciocan C, Godono A, Tardon A, Rodriguez-Suarez MM, Fernandez-Tardon G, Jimeno-Demuth FJ, Castro-Delgado RV, Iglesias Cabo T, Scapellato ML, Liviero F, Moretto A, Mason P, Pavanello S, Volpin A, Vimercati L, Tafuri S, De Maria L, Sponselli S, Stefanizzi P, Caputi A, Gobba F, Modenese A, Casolari L, Garavini D, D'Elia C, Mariani S, Filon FL, Cegolon L, Negro C, Ronchese F, Rui F, De Michieli P, Murgia N, Dell'Omo M, Muzi G, Fiordi T, Gambelunghe A, Folletti I, Mates D, Calota VC, Neamtu A, Perseca O, Staicu CA, Voinoiu A, Fabiánová E, Bérešová J, Adamčáková ZK, Nedela R, Lesňáková A, Holčíková J, Boffetta P, Abedini M, Ditano G, Asafo SS, Visci G, Violante FS, Zunarelli C, Verlato G
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Temporal trends of COVID-19 antibodies in vaccinated healthcare workers undergoing repeated serological sampling: An individual-level analysis within 13 months in the ORCHESTRA cohort

  • Collatuzzo, G.
  • De Palma, G.
  • Violante, F. S.
  • Rodríguez Suárez, Marta María
This project has received funding from the EU Horizon 2020 research and innovation programme under the ORCHESTRA project Grant Agreement No. 101016167, Collatuzzo G., De Palma G., Violante F.S., Porru S., Larese Filon F., Fabianova E., Violán C., Vimercati L., Leustean M., Rodriguez-Suarez M.M., Sansone E., Sala E., Zunarelli C., Lodi V., Monaco M.G.L., Spiteri G., Negro C., Beresova J., Carrasco-Ribelles L.A., Tafuri S., Asafo S.S., Ditano G., Abedini M., Boffetta P.